KZIA · Kazia Therapeutics Limited American Depositary Shares
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KZIA by emailGet an email when KZIA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KZIA, unsubscribe in one click. Privacy
📣 What KZIA Says Is Next
in 2028 · “Clinical updates are anticipated throughout 2027, with a full readout anticipated in 2028.”
Company press release, Sep 1, 2026 · SEC filing
the end of 2026 · “The Company expects sites for this expansion to be activated and the first patient enrolled before the end of 2026, with full enrollment anticipated by the end of 2027.”
Company press release, Sep 1, 2026 · SEC filing
this year · “This gives us the opportunity to enrich for the patients where this biology matters most and brings precision medicine to HR+ breast cancer.” This benchmarking work is ongoing, and Kazia expects to present additional data later this year, including further cellular, molecular and epigenetic characterization of paxalisib relative to other PI3K/mTOR inhibitors.”
Company press release, Sep 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KZIA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KZIA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.